The phase 3 data arrived later and from an unusual source: the REDEFINE 1 trial, which included a cagrilintide 2.4 mg monotherapy arm alongside CagriSema, semaglutide 2.4 mg and placebo across 3,417 adults with obesity or overweight and at least one comorbidity, without type 2 diabetes
Neuroprotective Effects: Emerging research suggests that BPC-157 may offer protective benefits to the brain and nervous system, potentially aiding in recovery from neurological injuries
For example, enzymes SOD, Cat, and GPx, and transition-metal binding proteins, such as transferrin, ferritin, and ceruloplasmin, inactivate free radicals ( 2 O 2 levels, GPx also participates in detoxification by converting lipid peroxides to the corresponding alcohols
This dose was chosen for further assessment in the subsequent phase III studies of serelaxin for AHF [21]
Cardiovascular efficacy and safety are currently being assessed in a dedicated outcomes trial